



## **Reminder: Exelixis Announces December 12 Webcast of Its Fourth Annual R&D Day**

December 8, 2008

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Dec. 8, 2008--Exelixis, Inc. (Nasdaq:EXEL) announced today that it will hold its Fourth Annual R&D Day on Friday, December 12, 2008 from 10:00 a.m. EST / 7:00 a.m. PST to 2:00 p.m. EST / 11:00 a.m. PST in New York. Exelixis management will discuss the company's corporate strategy, financial outlook and development pipeline.

The event will be webcast and may be accessed in the Event Calendar page under Investors at <http://www.exelixis.com>.

An archive of this webcast will be available until 9:00 p.m. PST/12:00 a.m. EST on January 12, 2009. Access numbers for this replay are: 1-888-286-8010 (domestic) and 1-617-801-6888 (international); the replay passcode number is: 90996892.

### **About Exelixis**

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb, Genentech, Wyeth Pharmaceuticals, and Daiichi-Sankyo. For more information, please visit the company's web site at [www.exelixis.com](http://www.exelixis.com).

Exelixis and the Exelixis logo are registered U.S. trademarks.

CONTACT: Exelixis, Inc.

Charles Butler, 650-837-7277 (Investors) Senior Director, Corporate Communications

[cbutler@exelixis.com](mailto:cbutler@exelixis.com)

Soleil Maxwell Harrison, 650-837-7012 (Media) Senior Manager, Corporate Communications

[sharrison@exelixis.com](mailto:sharrison@exelixis.com)

Source: Exelixis, Inc.